Prostate Boost Irradiation With Stereotactic Body RT (SBRT)
Status:
Recruiting
Trial end date:
2022-01-01
Target enrollment:
Participant gender:
Summary
A randomized controlled open-label trial in patients with high risk prostate cancer. Eligible
and consenting patients will be randomly allocated to receive stereotactic body radiotherapy
(SBRT) boost to prostate or conventional radiotherapy boost to prostate in 1:1 ratio.
Prostate radiotherapy boost will be administered after standard pelvic radiotherapy. Subjects
will be followed for 24 months post radiation treatment for Quality of Life assessment and
toxicity.